Recombinant and high-density lipoprotein complexed forms of serum paraoxonase are stable, do not cause toxic effects and show efficacy against organophosphate poisoning in mice, so have the potential to treat organophosphate toxicity and atherosclerosis in humans.

Knowledge of adverse drug reactions and the Yellow Card reporting scheme is inadequate among doctors at a teaching hospital in Lagos, Nigeria, and education and training were recognised as the best ways of improving reporting.